


Key Advocacy Takeaways

Brand Drugs Drive Costs. Generics Drive Savings.



Total Savings from Generics and Biosimilars

- Total generic and biosimilar savings in 2024:
 \$467 billion
- Total generic and biosimilar savings for the past ten years: \$3.4 trillion
- Generic share of total U.S. prescriptions filled:90 percent
- Generic share of total U.S. prescription drug spending: 12 percent
- Generic share of total U.S. healthcare spending:1.2 percent
- Total generic savings in Medicare in 2024:
 \$142 billion (\$2,643 per beneficiary)
- Total generic savings in Medicaid in 2024:
 \$62.1 billion (\$782 per enrollee)

Biosimilar Savings

- Biosimilar savings in 2024: \$20.2 billion
- Total savings since first biosimilar entry in 2015: \$56.2 billion
- Total days of patient therapy with biosimilars since 2015: 3.3 billion
- Incremental days of patient therapy that would not have occurred without biosimilar competition: 460 million